INFINIUM

Infinium Pharmachem Share Price

₹312.45 -13.55 (-4.16%)

21 Nov, 2024 14:28

SIP TrendupStart SIP in INFINIUM

Start SIP

Performance

  • Low
  • ₹312
  • High
  • ₹323
  • 52 Week Low
  • ₹178
  • 52 Week High
  • ₹393
  • Open Price₹323
  • Previous Close₹326
  • Volume6,000

Investment Returns

  • Over 1 Month -4.74%
  • Over 3 Month + 58.6%
  • Over 6 Month + 41.06%
  • Over 1 Year + 22.67%
SIP Lightning

Smart Investing Starts Here Start SIP with Infinium Pharmachem for Steady Growth!

Invest Now

Infinium Pharmachem Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -
  • PEG Ratio
  • -
  • Market Cap Cr
  • 435
  • P/B Ratio
  • 7.4
  • Average True Range
  • 12.68
  • EPS
  • 8.12
  • Dividend Yield
  • 0
  • MACD Signal
  • 5.84
  • RSI
  • 52.04
  • MFI
  • 32.99

Infinium Pharmachem Financials

Infinium Pharmachem Technicals

EMA & SMA

Current Price
₹312.45
-13.55 (-4.16%)
pointer
  • stock-down_img
  • Bullish Moving Average 7
  • stock-up_img
  • Bearish Moving Average 9
  • 20 Day
  • ₹326.74
  • 50 Day
  • ₹306.76
  • 100 Day
  • ₹279.26
  • 200 Day
  • ₹252.96

Resistance and Support

322.35 Pivot Speed
  • R3 340.60
  • R2 333.30
  • R1 329.65
  • S1 318.70
  • S2 311.40
  • S3 307.75

What's your outlook on Infinium Pharmachem?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Infinium Pharmachem Ltd has an operating revenue of Rs. 419.53 Cr. on a trailing 12-month basis. An annual revenue growth of 19% is outstanding, Pre-tax margin of 11% is healthy, ROE of 19% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 33% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 61 which is a FAIR score but needs to improve its earnings, a RS Rating of 84 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 22 indicates it belongs to a strong industry group of Comml Svcs-Healthcare and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Infinium Pharmachem Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results & Others To consider other business matters. issue in the ratio of 1:1 of Rs. 10/-.
2024-05-29 Audited Results
2023-10-27 Quarterly Results
2023-08-02 Bonus issue
2023-05-17 Audited Results
Date Purpose Remarks
2023-09-13 Bonus Rs.0.00 issue in the ratio of 1:1 of Rs. 10/-.

Infinium Pharmachem F&O

Infinium Pharmachem Shareholding Pattern

73.05%
23.97%
2.98%

About Infinium Pharmachem

  • NSE Symbol
  • INFINIUM
  • BSE Symbol
  • Managing Director
  • Mr. Sanjaykumar Viththalbhai Patel
  • ISIN
  • INE0MRE01011

Similar Stocks to Infinium Pharmachem

Infinium Pharmachem FAQs

Infinium Pharmachem share price is ₹312 As on 21 November, 2024 | 14:14

The Market Cap of Infinium Pharmachem is ₹434.8 Cr As on 21 November, 2024 | 14:14

The P/E ratio of Infinium Pharmachem is As on 21 November, 2024 | 14:14

The PB ratio of Infinium Pharmachem is 7.4 As on 21 November, 2024 | 14:14

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23